{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-013631","form_type":"8-K","ticker":"AMIX","cik":"0001617867","company_name":"Autonomix Medical, Inc.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.040196+00:00","generated_at":"2026-05-23T02:23:23.444608+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Autonomix PoC1 trial meets objectives; initiates PoC2 expansion study for visceral cancer pain","bullets":["All 20 patients enrolled; 19 treated via transvascular RF ablation; 84% femoral-access responders achieved 53.3% mean VAS pain reduction at 7 days.","100% of responding patients zero opioid use at 7 days post-procedure; 73% remained opioid-free at 4-6 weeks follow-up.","No device- or procedure-related serious adverse events; 6 subjects died from disease progression unrelated to the procedure.","PoC2 phase begins Q2 2025, targeting additional visceral cancers (liver, gall bladder, bile duct) and earlier-stage pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-013631","json":"https://secwatch.observer/filing/0001437749-25-013631.json","markdown":"https://secwatch.observer/filing/0001437749-25-013631.md","text":"https://secwatch.observer/filing/0001437749-25-013631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1617867/000143774925013631/0001437749-25-013631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1617867/000143774925013631/amix20250429_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:23:23.444608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}